Since GSPE acts as a regulator of the Keap1/Nrf2/ARE signaling pathway [12], we hypothesized that the Nrf2/HO-1 signaling pathway could serve as a potential therapeutic target for GSPE to delay the progression of DKD. Here, KEAP1 is linked to diabetic kidney disease.